These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 9035736)
1. [Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. II. Combined analysis of immunogenicity of composite peptides in rabbits]. Isaruliants MG; Ruden U; Wahren B Biokhimiia; 1996 Jul; 61(7):1230-40. PubMed ID: 9035736 [TBL] [Abstract][Full Text] [Related]
2. [Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. I. Maintenance of antigenic properties of HIV-1 B-epitopes]. Isaguliants MG; Koshida R; Ruden U; Varen B Biokhimiia; 1996 Jul; 61(7):1221-9. PubMed ID: 9035735 [TBL] [Abstract][Full Text] [Related]
3. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits. Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891 [TBL] [Abstract][Full Text] [Related]
4. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661 [TBL] [Abstract][Full Text] [Related]
5. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547 [TBL] [Abstract][Full Text] [Related]
6. The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides. Partidos C; Stanley C; Steward M Eur J Immunol; 1992 Oct; 22(10):2675-80. PubMed ID: 1382995 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. Viveros M; Dickey C; Cotropia JP; Gevorkian G; Larralde C; Broliden K; Levi M; Burgess A; Cao C; Weiner DB; Agadjanyan MG; Ugen KE Virology; 2000 Apr; 270(1):135-45. PubMed ID: 10772986 [TBL] [Abstract][Full Text] [Related]
8. Immunogenic combinations of HIV-1 B- and heterologous T-cell epitopes. Isaguliants M; Rudén U; Gilljam G; Wahren B Immunol Lett; 1994 Oct; 42(3):173-8. PubMed ID: 7534271 [TBL] [Abstract][Full Text] [Related]
9. Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope. Palacios-Rodríguez Y; Gazarian T; Rowley M; Majluf-Cruz A; Gazarian K J Microbiol Methods; 2007 Feb; 68(2):225-35. PubMed ID: 17046088 [TBL] [Abstract][Full Text] [Related]
10. Antigenic properties of phage displayed peptides comprising disulfide-bonded loop of the immunodominant region of HIV-1 gp41. Cano A; Viveros M; Acero G; Govezensky T; Munguia ME; Gonzalez E; Soto L; Gevorkian G; Manoutcharian K Immunol Lett; 2004 Sep; 95(2):207-12. PubMed ID: 15388262 [TBL] [Abstract][Full Text] [Related]
11. Sequential order of T and B cell epitopes affects immunogenicity but not antibody recognition of the B cell epitope. Denton G; Hudecz F; Kajtár J; Murray A; Tendler SJ; Price MR Pept Res; 1994; 7(5):258-64. PubMed ID: 7531518 [TBL] [Abstract][Full Text] [Related]
12. [Construction of peptide mimetics of an epitope of the human immunodeficiency virus (HIV-1) gp41 protein, recognized by virus-neutralizing antibodies 2F5]. Tumanova OIu; Kuvshinov VN; Azaev MSh; Masharskiĭ AE; Klimov NA; Kozlov AP; Il'ichev AA; Sandakhchiev LS Mol Biol (Mosk); 2001; 35(1):146-51. PubMed ID: 11234374 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice. Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490 [TBL] [Abstract][Full Text] [Related]
14. Mapping major and minor T-cell epitopes in vitro and their immunogenic or tolerogenic effect in vivo in non-human primates. Walker PR; Smerdon R; Haron J; Lehner T Immunology; 1993 Oct; 80(2):209-16. PubMed ID: 7505256 [TBL] [Abstract][Full Text] [Related]
15. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
17. Epitope-specific antibody and suppression of autoantibody responses against a hybrid self protein. Lohnas GL; Roberts SF; Pilon A; Tramontano A J Immunol; 1998 Dec; 161(12):6518-25. PubMed ID: 9862676 [TBL] [Abstract][Full Text] [Related]
18. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708 [TBL] [Abstract][Full Text] [Related]
19. Induction of primary antigen-specific immune reponses in SCID-hu-PBL by coupled T-B epitopes. Ifversen P; Mårtensson C; Danielsson L; Ingvar C; Carlsson R; Borrebaeck CA Immunology; 1995 Jan; 84(1):111-6. PubMed ID: 7534259 [TBL] [Abstract][Full Text] [Related]
20. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. Opalka D; Pessi A; Bianchi E; Ciliberto G; Schleif W; McElhaugh M; Danzeisen R; Geleziunas R; Miller M; Eckert DM; Bramhill D; Joyce J; Cook J; Magilton W; Shiver J; Emini E; Esser MT J Immunol Methods; 2004 Apr; 287(1-2):49-65. PubMed ID: 15099755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]